非酒精性脂肪性肝病治疗研究进展

doi:10.3969/j.issn.1672-5069.2019.01.038

Abstract

Abstract: Non-alcoholic fatty liver disease（NAFLD） is a global public health problem. Adjusting lifestyle and maintaining a healthy mental state are the cornerstones in dealing with patients with NAFLD. This article focuses on the recent progress at home and abroad in medical treatment of NAFLD and reviews the safety and efficacy of targeted therapies in different stages of oxidative stress,inflammatory response,lipid metabolism,fibrogenesis,and apoptosis.

Key words: Nonalcoholic fatty liver diseases, Oxidative stress, Treatment

Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.

References

[1] Panasevich MR,Meers GM,Linden MA,et al.High fat,high fructose,high cholesterol feeding causes severe NASH and cecal microbiota dysbiosis in juvenile ossabaw swine. Am J Physiol Endocrinol Metab,2017,341(1):E78-E92.
[2] Al-Gayyar MM,Shams ME,Barakat EA.Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome:impact of nonalcoholic fatty liver disease. Pharm Biol,2012,50(3):297-303.
[3] Nakamura M,Suetsugu A,Hasegawa K,et al.Choline-efficient-diet-induced fatty liver is a metastasis-resistant microenviron-ment. Anticancer Res,2017,37(7):3429-3434.
[4] Zhai X,Ren D,Luo Y,et al.Chemical characteristics of an Ilex Kuding tea polysaccharide and its protective effects against high fructose-induced liver injury and vascular endothelial dysfunction in mice. Food Funct,2017,8(7):2536-2547.
[5] Johnson S,Koh WP,Wang R,et al.Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study.Cancer Causes Control,2011,22(3):503-510.
[6] Mokhtari Z,Gibson DL,Hekmatdoost A.Nonalcoholic fatty liver disease,the gut microbiome,and diet. Adv Nutr,2017,8(2):240-252.
[7] Zhang HJ,He J,Pan LL,et al.Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease:A randomized clinical trial. JAMA Intern Med,2016,176(8):1074-1082.
[8] Oh S,So R,Shida T,et al.High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease.Sci Rep,2017,7:43029.
[9] Hashida R,Kawaguchi T,Bekki M,et al.Aerobic vs resistance exercise in non-alcoholic fatty liver disease:A systematic review. J Hepatol,2017,66(1):142-152.
[10] Oh S,Shida T,Yamagishi K,et al.Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease:a retrospective study. Hepatology,2015,61(4):1205-1215.
[11] Katsagoni CN,Georgoulis M,Papatheodoridis GV,et al.Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease:A meta-analysis.Metabolism,2017, 68:119-132.
[12] Youssef NA,Abdelmalek MF,Binks M,etal. Associations of depression,anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int,2013,33(7):1062-1070.
[13] Alcala M,Calderon-Dominguez M,Serra D,et al.Short-term vitamin E treatment impairs reactive oxygen species signaling required for adipose tissue expansion,resulting in fatty liver and insulin resistance in obese mice. PLoS One,2017,12(10):e0186579.
[14] Lavine JE,Schwimmer JB,Van Natta ML,et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:the TONIC randomized controlled trial.JAMA,2011,305(16):1659-1668.
[15] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67(1):328-357.
[16] Lippman SM,Klein EA,Goodman PJ,et al.Effect of selenium and vitamin E on risk of prostate cancer and other cancers:the selenium and vitamin E cancer prevention trial (SELECT).JAMA,2009,301(1):39-51.
[17] Okada Y,Yamaguchi K,Nakajima T,et al.Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. Liver Int,2013,33(2):301-311.
[18] Athyros VG,Mikhailidis DP,Didangelos TP,et al.Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome:a randomised study. Curr Med Res Opin,2006,22(5):873-883.
[19] Lefebvre E,Moyle G,Reshef R,et al.Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis.PLoS One,2016,11(6):e0158156.
[20] Friedman SL,Ratziu V,Harrison SA,et al.A randomized,placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.Hepatology,2017,294:77.
[21] Liss KH,Finck BN.PPARs and nonalcoholic fatty liver disease. Biochimie,2017,136:65-74.
[22] Ratziu V,Harrison SA,Francque S,et al.Elafibranor,an agonist of the peroxisome proliferator-activated receptor-α and-δ,induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology,2016,150(5):1147-1159.
[23] Geier A,Rau M.Emerging therapies for NASH-the future is now. Expert Rev Clin Pharmacol,2017,10(5):467-469.
[24] Fang S,Suh JM,Reilly SM,et al.Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med,2015,21(2):159-165.
[25] Neuschwander-Tetri BA,Loomba R,Sanyal AJ,et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):a multicentre,randomised, placebo-controlled trial.Lancet,2015,385(9972):956-965.
[26] Armstrong LE,Guo GL.Role of FXR in liver inflammation during nonalcoholic steatohepatitis. Curr Pharmacol Rep,2017,3(2):92-100.
[27] Armstrong MJ,Hull D,Guo K,et al.Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol,2016,64(2):399-408.
[28] Pi-Sunyer X,Astrup A,Fujioka K,et al.A randomized,controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med,2015,373(1):11-22.
[29] He Q,Sha S,Sun L,et al.GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. Biochem Biophys Res Commun,2016,476(4):196-203.
[30] Armstrong MJ,Gaunt P,Aithal GP,et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN):a multicentre,double-blind,randomised,placebo-controlled phase 2 study.Lancet,2016,387(10019):679-690.

Treatment of patients with nonalcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[2]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[3]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[4]	Gao Zhiliang, Zhu Xiang. How to achieve the clinical cure of hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 305-308.
[5]	Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.
[6]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[7]	Guideline for diagnosis, treatment of liver failure. [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 164-171.
[8]	Zhao Xiaofei, Lin Dongdong, Li Ning, Zang Yunjin, Guo Qingliang, Wu Juanshan. Application of warfarin in dealing with portal vein thrombosis in patients with liver cirrhosis after splenectomy and devascularization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 240-243.
[9]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[10]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[11]	Li Yue, Ding Huiguo.. Current diagnosis and treatment of chylous ascites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 665-668.
[12]	Cao Fenghua, Jing Jisheng, Zhao Wei, et al.. Clinical efficacy and safety of large dose of domestic interferon-α2b and ribavirin in the treatment of patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 729-732.
[13]	Zhou Zhiqing, Huang Yongdong. Efficacy of polyene phosphatidylcholine in patients with moderate -to-severe nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 733-736.
[14]	Cao Haixia, Fan Jiangao. Brief introduction of ESPGHAN recommendation for the diagnosis and treatment of children with Wilson's disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 502-504.
[15]	Wang Nian, Wei Chunling, Jiang Shishuang, et al. Protective effect of neferine on mice with D-GalN / LPS-induced acute liver injury by inhibiting oxidative stress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 545-548.